Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 100 articles:
HTML format
Text format



Single Articles


    July 2018
  1. DIERAS V, Rugo HS, Schnell P, Gelmon K, et al
    Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
    J Natl Cancer Inst. 2018 Jul 18. pii: 5055701. doi: 10.1093.
    PubMed     Text format     Abstract available



  2. Corrigendum to "Cost and Complications of Local Therapies for Early-Stage Breast Cancer".
    J Natl Cancer Inst. 2018 Jul 16. pii: 5054617. doi: 10.1093.
    PubMed     Text format    


  3. LU DL, Le Cornet C, Sookthai D, Johnson TS, et al
    Circulating 27-Hydroxycholesterol and Breast Cancer Risk: Results From the EPIC-Heidelberg Cohort.
    J Natl Cancer Inst. 2018 Jul 16. pii: 5054612. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. DAVIS LYNN BC, Rosenberg PS, Anderson WF, Gierach GL, et al
    Black-White Breast Cancer Incidence Trends: Effects of Ethnicity.
    J Natl Cancer Inst. 2018 Jul 5. pii: 5049141. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  5. LAMBERTINI M, Campbell C, Bines J, Korde LA, et al
    Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.
    J Natl Cancer Inst. 2018 Jun 5. pii: 5033460. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. CATHCART-RAKE E, Gast KC, Ruddy KJ
    What Can We Learn From Menstrual Patterns After Treatment for HER2-Positive Breast Cancer?
    J Natl Cancer Inst. 2018 Jun 5. pii: 5033462. doi: 10.1093.
    PubMed     Text format    



  7. Corrigendum to "Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer".
    J Natl Cancer Inst. 2018;110:684.
    PubMed     Text format    


    May 2018
  8. PATTERSON RE, Marinac CR, Sears DD, Kerr J, et al
    The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes.
    J Natl Cancer Inst. 2018 May 18. pii: 4999668. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. LOHMANN AE, Pimentel I, Goodwin PJ
    Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer.
    J Natl Cancer Inst. 2018 May 18. pii: 4999672. doi: 10.1093.
    PubMed     Text format    


    April 2018
  10. DESMEDT C, Demicheli R, Fornili M, Bachir I, et al
    Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.
    J Natl Cancer Inst. 2018 Apr 30. pii: 4975381. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. JAYASEKERA J, Li Y, Schechter CB, Jagsi R, et al
    Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.
    J Natl Cancer Inst. 2018 Apr 28. pii: 4990602. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. BIDARD FC, Michiels S, Riethdorf S, Mueller V, et al
    Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
    J Natl Cancer Inst. 2018 Apr 12. pii: 4969338. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. CHOI HJ, Joo HS, Won HY, Min KW, et al
    Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  14. VERMA V, Simone CB 2nd, Mishra MV
    Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    March 2018
  15. MATIKAS A, Foukakis T, Bergh J
    RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Mar 29. pii: 4956469. doi: 10.1093.
    PubMed     Text format    


  16. HAWK E, Maresso KC, Brown P
    NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.
    J Natl Cancer Inst. 2018 Mar 15. pii: 4938606. doi: 10.1093.
    PubMed     Text format    


  17. RITZWOLLER DP, Hassett MJ, Uno H, Cronin AM, et al
    Development, Validation, and Dissemination of a Breast Cancer Recurrence Detection and Timing Informatics Algorithm.
    J Natl Cancer Inst. 2018;110:273-281.
    PubMed     Text format     Abstract available


    February 2018
  18. GAIL MH, Pfeiffer RM
    Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening.
    J Natl Cancer Inst. 2018 Feb 27. pii: 4912416. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. ZACHARIAE R, Amidi A, Damholdt MF, Clausen CDR, et al
    Internet-Delivered Cognitive-Behavioral Therapy for Insomnia in Breast Cancer Survivors: A Randomized Controlled Trial.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881759. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. OESTERREICH S, Lucas PC, McAuliffe PF, Bruno TC, et al
    Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881762. doi: 10.1093.
    PubMed     Text format    


  21. DESMEDT C, Salgado R, Fornili M, Pruneri G, et al
    Immune Infiltration in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881757. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. IRWIN MR
    Innovation in the Treatment of Insomnia in Breast Cancer Survivors.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881761. doi: 10.1093.
    PubMed     Text format    


  23. BROWN J, Rathbone E, Hinsley S, Gregory W, et al
    Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
    J Natl Cancer Inst. 2018 Feb 7. pii: 4842040. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. HEINDL A, Sestak I, Naidoo K, Cuzick J, et al
    Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  25. TROESTER MA, Sun X, Allott EH, Geradts J, et al
    Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  26. BANDOS H, Melnikow J, Rivera DR, Swain SM, et al
    Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  27. RIVERA DR, Ganz PA, Weyrich MS, Bandos H, et al
    Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  28. JAGSI R, Momoh AO, Qi J, Hamill JB, et al
    Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    January 2018
  29. LINDSTROM LS, Yau C, Czene K, Thompson CK, et al
    Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    J Natl Cancer Inst. 2018 Jan 19. pii: 4780395. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. OZTURK TOPCU T, Jerzak KJ, Warner E
    RE: Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2018 Jan 10. pii: 4797407. doi: 10.1093.
    PubMed     Text format    


  31. LASKY-SU JA, Zeleznik OA, Eliassen AH
    Using Metabolomics to Explore the Role of Postmenopausal Adiposity in Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795354. doi: 10.1093.
    PubMed     Text format    


  32. MOORE SC, Playdon MC, Sampson JN, Hoover RN, et al
    A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795343. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. SCHRIJVER WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, et al
    Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Jan 5. pii: 4791841. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  35. GOLDVASER H, Barnes TA, Seruga B, Cescon DW, et al
    Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  36. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    December 2017
  37. POORVU PD, Winer EP
    Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718502. doi: 10.1093.
    PubMed     Text format    


  38. KURIAN AW, Bondarenko I, Jagsi R, Friese CR, et al
    Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718501. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. GLUZ O, Nitz U, Liedtke C, Christgen M, et al
    Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
    J Natl Cancer Inst. 2017 Dec 8. pii: 4698155. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  40. BELKACEMI Y, Kuten A
    RE: Regional Nodal Irradiation After Breast-Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    J Natl Cancer Inst. 2017 Nov 21. pii: 4645256. doi: 10.1093.
    PubMed     Text format    


  41. MEIER M, Orr N
    Genetic Determinants of Breast Cancer Risk in Childhood Cancer Survivors.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  42. MORTON LM, Sampson JN, Armstrong GT, Chen TH, et al
    Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  43. DESHMUKH AA, Shirvani SM, Lal L, Swint JM, et al
    Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  44. SCHWARZ LJ, Hutchinson KE, Rexer BN, Estrada MV, et al
    An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    October 2017
  45. LAMBERTINI M, Kroman N, Ameye L, Cordoba O, et al
    Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2017 Oct 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  46. VISSCHER DW, Frank RD, Carter JM, Vierkant RA, et al
    Breast Cancer Risk and Progressive Histology in Serial Benign Biopsies.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available



  47. Restarting Adjuvant Hormone Therapy Improves Breast Cancer Outcomes.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  48. HE W, Smedby KE, Fang F, Olsson H, et al
    Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  49. HERMELINK K, Buhner M, Sckopke P, Neufeld F, et al
    Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  50. ROBSON ME, Reiner AS, Brooks JD, Concannon PJ, et al
    Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    September 2017
  51. BYRNE C, Ursin G, Martin CF, Peck JD, et al
    Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    August 2017
  52. POLLACK CE, Soulos PR, Herrin J, Xu X, et al
    The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  53. SCHMIDT MK, van den Broek AJ, Tollenaar RA, Smit VT, et al
    Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  54. GINGRAS I, Holmes E, De Azambuja E, Nguyen DH, et al
    Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    July 2017
  55. SHAFAEE MN, Ellis MJ
    Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  56. WU X, Ye Y, Barcenas CH, Chow WH, et al
    Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  57. ROJAS PA, May M, Sequeira GR, Elia A, et al
    Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  58. GOETZ MP, Kalari KR, Suman VJ, Moyer AM, et al
    Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  59. KUCHENBAECKER KB, McGuffog L, Barrowdale D, Lee A, et al
    Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    June 2017
  60. SAMANTA SK, Sehrawat A, Kim SH, Hahm ER, et al
    Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  61. DAVE B, Gonzalez DD, Liu ZB, Li X, et al
    Role of RPL39 in Metaplastic Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available



  62. Higher consumption of grilled, barbecued, and smoked meat linked to increased mortality risk among breast cancer survivors.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


    May 2017
  63. KERLIKOWSKE K, Gard CC, Tice JA, Ziv E, et al
    Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  64. WALTER JR, Xu S, Woodruff TK
    A Call for Fertility Preservation Coverage for Breast Cancer Patients: The Cost of Consistency.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    April 2017
  65. NOLAN E, Vaillant F, Visvader JE, Lindeman GJ, et al
    RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    J Natl Cancer Inst. 2017 Apr 4. doi: 10.1093.
    PubMed     Text format    


  66. SCHERNHAMMER ES
    RE: Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  67. HANSEN J
    RE: Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  68. ERREN TC, Morfeld P, Gross JV
    RE: Night Shiftwork and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  69. STEVENS RG
    RE: Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  70. GARRIDO-CASTRO AC, Winer EP
    Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy?
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


    March 2017
  71. MA R, Karthik GM, Lovrot J, Haglund F, et al
    Estrogen Receptor beta as a Therapeutic Target in Breast Cancer Stem Cells.
    J Natl Cancer Inst. 2017;109:1-14.
    PubMed     Text format     Abstract available


    February 2017
  72. ERIKSEN KT, McElroy JA, Harrington JM, Levine KE, et al
    Urinary Cadmium and Breast Cancer: A Prospective Danish Cohort Study.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  73. GREENLEE H, Hershman DL, Shi Z, Kwan ML, et al
    BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  74. BANEGAS MP, John EM, Slattery ML, Gomez SL, et al
    Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  75. SINDZINSKI A
    Risk of Heart Disease in Breast Cancer Patients Receiving Estrogen-Deprivation Therapy.
    J Natl Cancer Inst. 2017;109:2-3.
    PubMed     Text format    


  76. GREENLEE H, Hershman DL, Shi Z, Kwan ML, et al
    BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study.
    J Natl Cancer Inst. 2017;109:1-8.
    PubMed     Text format     Abstract available


  77. ERIKSEN KT, McElroy JA, Harrington JM, Levine KE, et al
    Urinary Cadmium and Breast Cancer: A Prospective Danish Cohort Study.
    J Natl Cancer Inst. 2017;109:1-7.
    PubMed     Text format     Abstract available


  78. SINDZINSKI A
    Risk of Heart Disease in Breast Cancer Patients Receiving Estrogen-Deprivation Therapy.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


    January 2017
  79. PARADA H JR, Steck SE, Bradshaw PT, Engel LS, et al
    Grilled, Barbecued, and Smoked Meat Intake and Survival Following Breast Cancer.
    J Natl Cancer Inst. 2017 Jan 4. pii: djw299. doi: 10.1093.
    PubMed     Text format     Abstract available


  80. KOTSOPOULOS J, Huzarski T, Gronwald J, Singer CF, et al
    Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  81. HILAKIVI-CLARKE L, Warri A, Bouker KB, Zhang X, et al
    Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  82. SMITH BD, Jiang J, Shih YC, Giordano SH, et al
    Cost and Complications of Local Therapies for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  83. PARKES EE, Walker SM, Taggart LE, McCabe N, et al
    Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  84. BENSE RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JB, et al
    Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  85. MAMOUNAS EP, Liu Q, Paik S, Baehner FL, et al
    21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  86. HAAS JS
    The Complexity of Achieving the Promise of Precision Breast Cancer Screening.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  87. SHIEH Y, Eklund M, Madlensky L, Sawyer SD, et al
    Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available



  88. Different Breast Cancer Treatment Options Vary Widely in their Cost-Effectiveness.
    J Natl Cancer Inst. 2017;109:1-2.
    PubMed     Text format    


    December 2016
  89. TRAVIS RC, Balkwill A, Fensom GK, Appleby PN, et al
    Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available



  90. Night Shift Work and Breast Cancer Risk.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    November 2016
  91. TER BRUGGE P, Kristel P, van der Burg E, Boon U, et al
    Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


  92. VISVANATHAN K, Yager JD
    Ethnic Variations in Estrogen and Its Metabolites: Sufficient to Explain Differences in Breast Cancer Incidence Rates?
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    October 2016
  93. MOORE SC, Matthews CE, Ou Shu X, Yu K, et al
    Endogenous Estrogens, Estrogen Metabolites, and Breast Cancer Risk in Postmenopausal Chinese Women.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


  94. VISVANATHAN K, Yager JD
    Ethnic Variations in Estrogen and Its Metabolites: Sufficient to Explain Differences in Breast Cancer Incidence Rates?
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    August 2016
  95. MARTIN LJ, Huszti E, Connelly PW, Greenberg CV, et al
    RE: Serum Lipids, Lipoproteins, and Risk of Breast Cancer: A Nested Case-Control Study Using Multiple Time Points.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


  96. TOOMEY S, Eustace AJ, Pritzker LB, Pritzker KP, et al
    RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


  97. SCHMIDT C
    Mammaprint Reveals Who Can Skip Chemotherapy for Breast Cancer.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    June 2016
  98. FILLON M
    Continuing To Smoke After Breast Cancer Diagnosis Lowers Survival Rate.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    April 2016
  99. AZVOLINSKY A
    Unraveling How Obesity Fuels Cancer.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


  100. JENKS S
    Digital Imaging of the Breast: Is a Synthetic View Better?
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: